N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 5 925 JPY 3.6% Market Closed
Market Cap: 416.2B JPY

Nippon Shinyaku Co Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nippon Shinyaku Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Net Income (Common)
ÂĄ30.5B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
18%
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Income (Common)
ÂĄ33.1B
CAGR 3-Years
-46%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Net Income (Common)
ÂĄ279.9B
CAGR 3-Years
65%
CAGR 5-Years
19%
CAGR 10-Years
-2%
Otsuka Holdings Co Ltd
TSE:4578
Net Income (Common)
ÂĄ449.1B
CAGR 3-Years
60%
CAGR 5-Years
26%
CAGR 10-Years
12%
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Income (Common)
ÂĄ397.2B
CAGR 3-Years
-12%
CAGR 5-Years
14%
CAGR 10-Years
21%
Astellas Pharma Inc
TSE:4503
Net Income (Common)
ÂĄ124.9B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
399.2B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 262.34 JPY
Overvaluation 28%
Intrinsic Value
Price
N

See Also

What is Nippon Shinyaku Co Ltd's Net Income (Common)?
Net Income (Common)
30.5B JPY

Based on the financial report for Jun 30, 2025, Nippon Shinyaku Co Ltd's Net Income (Common) amounts to 30.5B JPY.

What is Nippon Shinyaku Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
18%

Over the last year, the Net Income (Common) growth was 12%. The average annual Net Income (Common) growth rates for Nippon Shinyaku Co Ltd have been -11% over the past three years , 11% over the past five years , and 18% over the past ten years .

Back to Top